



Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2025

Sr. No	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from Operations	4,975	6,027	5,078	22,189
2	Other Income	359	296	196	7,489
3	Total Income	5,334	6,323	5,274	29,678
4	Expenses				
	Cost of Materials Consumed	345	192	286	800
	Cost of Construction	1,010	1,549	1,191	6,005
	Changes in Inventories of Finished Goods and WIP	174	(3)	131	111
	Employee Benefit Expenses	783	650	773	2,731
	Finance Costs	59	62	49	247
	Depreciation and amortisation expense	279	275	250	1,063
	Other Expenses	705	906	657	3,170
	Total Expenses	3,356	3,632	3,337	14,128
5	Profit Before Tax (3-4)	1,978	2,692	1,937	15,550
6	Tax Expenses				
	Current Tax	202	345	234	1,763
	Deferred Tax	(3)	128	(38)	(514)
	Short / (Excess) Provision of earlier years	-	(156)	-	(156)
7	Net Profit after tax for the Period	1,780	2,375	1,742	14,457
8	Share of Associate's Profit/(Loss)	4,384	4,470	3,840	16,610
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	6,164	6,845	5,582	31,068
10	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Profit or (Loss)	482	(2,626)	4,348	(3,511)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(69)	388	(490)	(108)
	B (i) Items that will be reclassified to Profit or (Loss)	31	106	(3)	188
11	Total Comprehensive Income/(Loss) for the Period	6,609	4,713	9,436	27,636
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				2,04,790
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.40	2.67	2.17	12.10





Alembic Limited
Segment wise Consolidated Revenue and Results

Sr. No	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,295	778	1,072	3,221
	b. Real Estate Business	3,680	5,248	4,006	18,967
	Total Income from Operations (Net)	4,975	6,027	5,078	22,189
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	273	188	50	473
	b. Real Estate Business	1,594	2,563	1,924	8,806
	Total	1,867	2,751	1,974	9,278
	Unallocable Income and Expenditure				
	(i) Interest Expense	(59)	(62)	(49)	(247)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	171	(12)	31	6,471
	(iii) Other Income / (Expense)	0	15	(20)	47
	Total Profit Before Tax	1,978	2,692	1,937	15,550
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	19,170	18,722	18,752	18,722
	b. Real Estate Business	46,822	44,313	39,663	44,313
	c. Unallocated	1,86,165	1,87,265	1,86,495	1,87,265
	Total	2,52,158	2,50,300	2,44,910	2,50,300
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,647	3,128	3,582	3,128
	b. Real Estate Business	10,857	9,947	8,987	9,947
	c. Unallocated	3,356	3,367	4,349	3,367
	Total	17,861	16,441	16,918	16,441

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2025 and year to date unaudited figures upto third quarter ended 31st December, 2024.



For Alembic Limited

[Signature]

Chirayu Amin
Chairman

Place : Vadodara
Date : 12th August, 2025

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2025

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from Operations	4,789	5,822	4,908	21,436
2	Other Income	346	278	189	7,451
3	Total Income	5,134	6,100	5,097	28,887
4	Expenses				
	Cost of Materials Consumed	345	192	286	800
	Cost of Construction	1,010	1,549	1,191	6,005
	Changes in Inventories of Finished Goods and WIP	174	(3)	131	111
	Employee Benefit Expenses	783	650	773	2,731
	Finance Costs	42	45	34	183
	Depreciation and amortisation expense	270	266	241	1,024
	Other Expenses	619	832	582	2,833
	Total Expenses	3,243	3,532	3,238	13,688
5	Profit Before Tax (3-4)	1,892	2,568	1,859	15,199
6	Tax Expenses				
	Current Tax	180	315	213	1,675
	Deferred Tax	(0)	126	(37)	(514)
	Short / (Excess) Provision of earlier years	-	(156)	-	(156)
7	Net Profit after tax for the Period	1,712	2,283	1,684	14,195
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or (Loss)	495	(2,673)	4,459	(3,457)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(71)	383	(510)	(132)
9	Total Comprehensive Income/(Loss) for the Period	2,136	(7)	5,633	10,606
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				56,250
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.67	0.89	0.66	5.53



Alembic Limited


Segment wise Standalone Revenue and Results

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,295	778	1,072	3,221
	b. Real Estate Business	3,493	5,043	3,835	18,214
	Total Income from Operations (Net)	4,789	5,822	4,908	21,436
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	273	188	50	473
	b. Real Estate Business	1,490	2,423	1,831	8,390
	Total	1,763	2,611	1,881	8,863
	Unallocable Income and Expenditure				
	(i) Interest Expense	(42)	(45)	(34)	(183)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	171	(12)	31	6,471
	(iii) Other Income / (Expense)	0	15	(20)	47
	Total Profit Before Tax	1,892	2,568	1,859	15,199
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	19,170	18,722	18,752	18,722
	b. Real Estate Business	45,574	43,080	38,784	43,080
	c. Unallocated	39,847	39,181	45,057	39,181
	Total	1,04,591	1,00,983	1,02,592	1,00,983
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,647	3,128	3,582	3,128
	b. Real Estate Business	9,944	9,022	8,154	9,022
	c. Unallocated	3,545	3,514	4,347	3,514
	Total	17,136	15,664	16,084	15,664

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2025 and year to date unaudited figures upto third quarter ended 31st December, 2024.



For Alembic Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 12th August, 2025

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2025 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31st March, 2025. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

5. The statement includes results of the following entities:

- i. Alembic City Limited (Subsidiary)
- ii. Alembic Pharmaceuticals Limited (Associate)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 915.46 lakhs, total net profit after tax of Rs.7.47 lakhs and total comprehensive income of Rs. 7.58 lakhs for the quarter ended 30th June, 2025. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,384.48 lakhs and total comprehensive income of Rs. 4,404.74 lakhs for the quarter ended 30th June, 2025, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036

Rachit Sheth

Rachit Sheth
Partner
Membership No.158289
Place: Vadodara
Date: 12th August, 2025
UDIN: 25158289BMHZZU6022



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 30th June, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31st March, 2025. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Rachit Sheth

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date:12th August, 2025

UDIN: 25158289BMHZZT4605

